iBio, Inc. (IBIO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

iBio, Inc. (IBIO) Healthcare & Pipeline Overview

iBio, Inc. stands out in the biotechnology sector by offering specialized contract development and manufacturing services, focusing on innovative therapeutic candidates and vaccines, while navigating a complex regulatory landscape.

What Is the Investment Thesis for IBIO?

iBio, Inc. is positioned to capitalize on significant growth opportunities within the biotechnology sector, particularly through its lead therapeutic candidate, IBIO-100, which targets systemic scleroderma and idiopathic pulmonary fibrosis. The global market for fibrosis treatments is projected to reach approximately $12 billion by 2027, presenting a substantial revenue opportunity. Additionally, the company's vaccine candidates against SARS-CoV-2 and classical swine fever could tap into the growing demand for effective vaccines, especially in the wake of the COVID-19 pandemic. iBio's strategic collaborations with leading institutions enhance its R&D capabilities and market access, potentially accelerating product development timelines. However, the company's current financial metrics reflect challenges, including a profit margin of -8245.7% and a gross margin of -76.7%, indicating the need for operational improvements and successful commercialization of its product pipeline. Investors should closely monitor the progress of iBio's clinical trials and strategic partnerships as key indicators of future performance.

Based on FMP financials and quantitative analysis

IBIO Key Highlights

Market capitalization of $19.3M reflects the company's current valuation in the biotechnology sector.

• Profit margin of -8245.7% indicates significant operational challenges that need addressing.
• Gross margin of -76.7% suggests high costs relative to revenue, highlighting the need for improved efficiency.
• Beta of 1.36 indicates higher volatility compared to the market, which may affect investor sentiment.
• No dividend yield as the company reinvests earnings into R&D and operational growth.

Who Are IBIO's Competitors?

IBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IBIO's Key Strengths?

Innovative product pipeline targeting significant unmet medical needs.

• Strong partnerships with academic and research institutions.
• Expertise in bioprocessing and contract manufacturing.

What Are IBIO's Weaknesses?

High operational costs leading to negative profit margins.

• Limited workforce may hinder scalability and growth.
• Dependence on successful clinical trials for future revenue.

What Could Drive IBIO Stock Higher?

Progress in clinical trials for IBIO-100, with potential milestones expected in 2026.

• Development of vaccine candidates IBIO-200 and IBIO-201, with preclinical results anticipated in the near term.
• Strategic collaborations with academic institutions that may lead to innovative product developments.

What Are the Key Risks for IBIO?

Financial-distress signal — its Altman Z-Score of -4.42 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-53.9%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Regulatory challenges that could delay the approval of therapeutic and vaccine candidates.
• Financial instability due to negative profit margins and reliance on external funding.
• Market competition from established pharmaceutical companies and emerging biotech firms.

What Are the Growth Opportunities for IBIO?

• Growth opportunity 1: The global market for systemic sclerosis treatments is projected to reach $12 billion by 2027. iBio's lead candidate, IBIO-100, is well-positioned to capture market share as it progresses through clinical trials, addressing a significant unmet medical need in this space.
• Growth opportunity 3: iBio's collaboration with The Texas A&M University System enhances its R&D capabilities, potentially leading to accelerated development timelines for its vaccine candidates. Successful outcomes could position iBio as a key player in the vaccine development arena.
• Growth opportunity 4: The bioprocessing segment is gaining traction as more companies outsource manufacturing. iBio's expertise in this area could attract new clients, expanding its revenue base and improving operational efficiencies.
• Growth opportunity 5: The increasing focus on personalized medicine and recombinant proteins presents an opportunity for iBio to diversify its offerings. By developing custom recombinant proteins, the company can tap into a growing market segment, further enhancing its service portfolio.

What Opportunities Does IBIO Have?

• Growing demand for vaccines and therapeutics post-COVID-19.
• Expansion of bioprocessing services as companies outsource manufacturing.
• Potential for diversification into personalized medicine and recombinant proteins.

What Threats Does IBIO Face?

• Intense competition in the biotechnology and pharmaceutical sectors.
• Regulatory hurdles and lengthy approval processes for new products.
• Market volatility affecting investor sentiment and funding availability.

What Are IBIO's Competitive Advantages?

• Specialized expertise in bioprocessing and contract manufacturing sets iBio apart from competitors.
• Strategic collaborations with leading research institutions enhance innovation and R&D capabilities.
• A focused product pipeline targeting significant unmet medical needs provides a competitive edge.
• The company's lean operational structure allows for agile decision-making and cost management.
• Established relationships with collaborators and customers foster trust and long-term partnerships.

What Does IBIO Do?

Founded in Bryan, Texas, iBio, Inc. has established itself as a key player in the biotechnology sector, specializing in contract development and manufacturing services for both collaborators and third-party customers. The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate, IBIO-100, is currently under development for investigational new drug status targeting systemic scleroderma and idiopathic pulmonary fibrosis, showcasing the company's commitment to addressing significant unmet medical needs. Additionally, iBio is advancing several vaccine candidates, including IBIO-200 and IBIO-201, which are in preclinical stages aimed at preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and IBIO-400 for treating classical swine fever. The company also provides a range of services including process development, manufacturing, filling and finishing, and bio analytic services, catering to diverse client needs. iBio has established strategic partnerships, such as a license agreement with Planet Biotechnology, Inc. for developing therapeutics for infectious diseases and collaborations with The Texas A&M University System and the University of Natural Resources and Life Sciences, Vienna. With a lean workforce of 16 employees, iBio is strategically positioned to leverage its innovative capabilities in the rapidly evolving biotechnology landscape.

What Products and Services Does IBIO Offer?

• Provides contract development and manufacturing services to biotechnology and pharmaceutical companies.
• Develops therapeutic candidates targeting systemic scleroderma and idiopathic pulmonary fibrosis.
• Advances vaccine candidates for the prevention of SARS-CoV-2 and classical swine fever.
• Offers process development, manufacturing, filling and finishing, and bio analytic services.
• Collaborates with academic and research institutions for innovative therapeutic development.
• Develops recombinant proteins for third parties on a catalog and custom basis.

How Does IBIO Make Money?

• Generates revenue through contract development and manufacturing services for third-party clients.
• Receives funding and royalties from collaborations and licensing agreements with research institutions.
• Monetizes its therapeutic and vaccine candidates upon successful development and commercialization.
• Offers specialized services to clients in need of bioprocessing and manufacturing expertise.
• Engages in strategic partnerships to enhance R&D capabilities and market access.

What Industry Does IBIO Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in technology and increasing demand for innovative therapies and vaccines. The global biotechnology market is projected to reach approximately $2.44 trillion by 2028, with a CAGR of 15.83%. iBio, Inc. operates in a competitive landscape characterized by a mix of established pharmaceutical companies and emerging biotech firms. The company's focus on contract development and manufacturing services positions it to leverage the growing trend of outsourcing in the biotech sector, as organizations seek specialized expertise to accelerate product development and reduce costs.

Who Are IBIO's Key Customers?

• Biotechnology companies seeking contract development and manufacturing services.
• Pharmaceutical firms requiring specialized bioprocessing expertise.
• Academic institutions collaborating on research and development projects.
• Government agencies funding vaccine development initiatives.
• Agricultural firms interested in vaccine candidates for livestock diseases.

iBio, Inc. Financial Trajectory

iBio, Inc. (IBIO) reported $0 in revenue for Q4 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $10.6M, with diluted EPS of $-0.10. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, IBIO averaged $-0.09 in diluted EPS.

Company Profile

iBio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, United States.

How iBio, Inc. Is Valued

iBio, Inc. carries a market capitalization of $19.3M, placing it in the micro-cap category. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $1.23, that implies approximately 308% upside potential. Relative to its peer group, IBIO's quantitative score of 19/100 is below the peer average of 64/100.

Return on equity for iBio, Inc. stands at -53.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.2%, showing how much profit it generates from its asset base. A current ratio of 11.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.0%, the inverse of the P/E and a quick read on earnings relative to price.

iBio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.42 places it in the distress zone, a signal of elevated financial risk.

iBio, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 6.9% below estimates on average.

Over the past six months, iBio, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 541K shares acquired (about $785K) — insiders putting money in tends to read as conviction.

IBIO Financials

IBIO Latest News

IBIO Analyst Consensus

IBIO MoonshotScore

What Investors Ask About iBio, Inc. (IBIO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources